Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for converting folate into its active form. This inhibition disrupts the synthesis of nucleotides needed for DNA, RNA, and protein production, thereby limiting the proliferation of rapidly dividing immune cells and cancer cells.

The specific dose of Metoject is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment goals. Dosage regimens vary widely between autoimmune indications and oncologic protocols, and the prescriber will tailor the schedule accordingly.

Metoject is classified as pregnancy category X, meaning it is contraindicated in pregnancy due to a high risk of fetal malformations and miscarriage. It is also not recommended during breastfeeding because methotrexate can be excreted in breast milk and may harm the infant.

To place an order, submit an enquiry on the Metoject product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.

Metoject (methotrexate) is an antimetabolite that interferes with folate metabolism, whereas many other chemotherapy agents target microtubules, DNA cross‑linking, or kinase pathways. Methotrexate is often used in combination regimens because of its distinct mechanism, and it can be administered via injection, offering flexibility compared with oral formulations of other agents.

Metoject should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Proper cold‑chain storage maintains drug stability and potency.

Metoject is supplied as an injectable solution and can be given intramuscularly, intravenously, or subcutaneously, depending on the clinical protocol. Administration is performed by a qualified healthcare professional under aseptic conditions, with dosage and frequency set by the treating physician.

The most serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to infection or bleeding, acute renal failure, and life‑threatening hypersensitivity reactions. Patients should be monitored regularly for signs of organ dysfunction and blood‑cell abnormalities.

Metoject should not be used by pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe liver disease, uncontrolled infections, or significant renal impairment without dose adjustment. It is also contraindicated in patients receiving live vaccines due to the risk of infection.